These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36946233)

  • 1. Physiologically based pharmacokinetic and pharmacodynamic modelling of alprazolam: Implications for anxiety and addiction.
    Burkat PM
    Br J Clin Pharmacol; 2023 Aug; 89(8):2569-2581. PubMed ID: 36946233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling of Diazepam: Unbound Interstitial Brain Concentrations Correspond to Clinical End Points.
    Burkat PM
    J Clin Pharmacol; 2022 Oct; 62(10):1297-1309. PubMed ID: 35533144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions.
    Sanna E; Pau D; Tuveri F; Massa F; Maciocco E; Acquas C; Floris C; Fontana SN; Maira G; Biggio G
    Arzneimittelforschung; 1999 Feb; 49(2):88-95. PubMed ID: 10083975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprazolam absorption kinetics affects abuse liability.
    Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
    Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration.
    Smith RB; Kroboth PD; Vanderlugt JT; Phillips JP; Juhl RP
    Psychopharmacology (Berl); 1984; 84(4):452-6. PubMed ID: 6152055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship.
    Wright CE; Sisson TL; Fleishaker JC; Antal EJ
    J Clin Pharmacol; 1997 Apr; 37(4):321-9. PubMed ID: 9115058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.
    Busto UE; Kaplan HL; Wright CE; Gomez-Mancilla B; Zawertailo L; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2000 Dec; 20(6):628-35. PubMed ID: 11106134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained-release formulation.
    Fleishaker JC; Phillips JP; Eller MG; Smith RB
    J Clin Pharmacol; 1989 Jun; 29(6):543-9. PubMed ID: 2754023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voltage-clamp evidence of GABA
    Fernandes H; Batalha V; Braksator E; Hebeisen S; Bonifácio MJ; Vieira-Coelho MA; Soares-da-Silva P
    Pharmacol Rep; 2022 Oct; 74(5):956-968. PubMed ID: 36097257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers.
    Venkatakrishnan K; Culm KE; Ehrenberg BL; Harmatz JS; Corbett KE; Fleishaker JC; Greenblatt DJ
    J Clin Pharmacol; 2005 May; 45(5):529-37. PubMed ID: 15831776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits.
    Lau CE; Heatherington AC
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1119-29. PubMed ID: 9399984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.
    Scavone JM; Greenblatt DJ; Goddard JE; Friedman H; Harmatz JS; Shader RI
    Eur J Clin Pharmacol; 1992; 42(4):439-43. PubMed ID: 1516609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of endogenous progesterone on alprazolam pharmacodynamics.
    McAuley JW; Friedman CI
    J Clin Psychopharmacol; 1999 Jun; 19(3):233-9. PubMed ID: 10350029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic response profiles of anxiolytic and sedative drugs.
    Chen X; Broeyer F; de Kam M; Baas J; Cohen A; van Gerven J
    Br J Clin Pharmacol; 2017 May; 83(5):1028-1038. PubMed ID: 27922194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cognitive effect of alprazolam in healthy volunteers].
    Drabant S; Tömlo J; Tóth M; Péterfai E; Klebovich I
    Acta Pharm Hung; 2006; 76(1):25-31. PubMed ID: 17094673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry.
    Saletu B; Grünberger J; Linzmayer L; Semlitsch HV; Anderer P; Chwatal K
    Br J Clin Pharmacol; 1994 Feb; 37(2):145-56. PubMed ID: 7910470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
    Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 2000 Jun; 20(3):338-46. PubMed ID: 10831021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects.
    Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
    J Clin Pharmacol; 1998 Jan; 38(1):14-21. PubMed ID: 9597554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alprazolam extended-release in panic disorder.
    Rickels K
    Expert Opin Pharmacother; 2004 Jul; 5(7):1599-611. PubMed ID: 15212610
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.